A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ledipasvir and Sofosbuvir (Harvoni)

Hepatitis C Virus NS5A Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2014-10-10
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
345 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Ledipasvir and Sofosbuvir used for?

Ledipasvir and Sofosbuvir is a Hepatitis C Virus NS5A Inhibitor medication tracked in Medicare Part D.

Is there a generic for Ledipasvir and Sofosbuvir?

No. Ledipasvir and Sofosbuvir is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ledipasvir and Sofosbuvir?

NADAC pricing data not currently available for this drug.

Is Ledipasvir and Sofosbuvir on the FDA shortage list?

No. Ledipasvir and Sofosbuvir is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Hepatitis C Virus NS5A Inhibitor1 alternative in D1
01
Elbasvir and Grazoprevir
Brand: ZEPATIER
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.